On this page
HALOG
Halcinonide Topical · Solution
Overview
Active ingredients
Source: NDC Directory| Ingredient | Strength | RxCUI | Monograph |
|---|---|---|---|
| Halcinonide | 1 mg/mL | 310669 | View |
Forms, strengths and routes
Source: NDC DirectoryPharmacologic classes are listed in the class section below.
Pharmacologic class
Source: NDC Directory| Class | Type | Browse |
|---|---|---|
| Corticosteroid Hormone Receptor Agonists [MoA] | MoA | All 215 members |
| Corticosteroid [EPC] | EPC | All 215 members |
Regulatory status
Source: Drugs@FDANDC Directory| Product | Trade name | Form | Strength | Ingredient | Status | TE | Flags |
|---|---|---|---|---|---|---|---|
| 017823-001 | HALOG | SOLUTION | HALCINONIDE | Prescription | AT | RLD |
Therapeutic equivalence
Source: Orange BookWhat this rating means: Therapeutically equivalent — bioequivalence demonstrated (topical dermatological products)
Codes beginning with “A” indicate products the FDA considers therapeutically equivalent. Codes beginning with “B” indicate bioequivalence has not been established. See methodology.
Approval history
Source: Drugs@FDA| Type | No. | Action | Status | Date | Review |
|---|---|---|---|---|---|
| Supplement | 24 | Manufacturing (CMC) | Approved | March 18, 2020 | N/A |
| Supplement | 23 | Labeling | Approved | September 29, 2004 | Standard |
| Supplement | 22 | Manufacturing (CMC) | Approved | October 8, 1996 | Standard |
| Supplement | 21 | Manufacturing (CMC) | Approved | June 23, 1992 | Standard |
| Supplement | 20 | Manufacturing (CMC) | Approved | June 27, 1989 | Standard |
| Supplement | 19 | Manufacturing (CMC) | Approved | March 2, 1988 | Standard |
| Supplement | 18 | Manufacturing (CMC) | Approved | July 30, 1985 | Standard |
| Supplement | 17 | Manufacturing (CMC) | Approved | January 22, 1985 | Standard |
| Supplement | 16 | Manufacturing (CMC) | Approved | August 30, 1984 | Standard |
| Supplement | 15 | Manufacturing (CMC) | Approved | May 31, 1984 | Standard |
| Supplement | 14 | Labeling | Approved | January 21, 1983 | — |
| Supplement | 13 | Manufacturing (CMC) | Approved | December 30, 1981 | Standard |
| Supplement | 11 | Manufacturing (CMC) | Approved | August 12, 1980 | Standard |
| Supplement | 10 | Manufacturing (CMC) | Approved | June 20, 1980 | Standard |
| Supplement | 5 | Labeling | Approved | April 18, 1980 | — |
| Supplement | 9 | Manufacturing (CMC) | Approved | February 13, 1980 | Standard |
| Supplement | 8 | Manufacturing (CMC) | Approved | January 29, 1980 | Standard |
| Supplement | 7 | Manufacturing (CMC) | Approved | April 18, 1979 | Standard |
| Supplement | 6 | Manufacturing (CMC) | Approved | January 10, 1979 | Standard |
| Supplement | 4 | Manufacturing (CMC) | Approved | May 12, 1978 | Standard |
| Supplement | 3 | Manufacturing (CMC) | Approved | January 9, 1978 | Standard |
| Supplement | 1 | Manufacturing (CMC) | Approved | August 24, 1977 | Standard |
| Original application | 1 | Type 3 - New Dosage Form | Approved | May 4, 1977 | Standard |
Prescribing information
Source: openFDA Drug LabelingReproduced verbatim from the Structured Product Labeling submitted to the FDA (effective 20251105). This is the manufacturer's labelling text, not a summary and not advice.
Indications and Usage
openFDA Drug LabelingINDICATIONS AND USAGE HALOG SOLUTION (Halcinonide Topical Solution, USP) 0.1% is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.
Dosage and Administration
openFDA Drug LabelingDOSAGE AND ADMINISTRATION Apply HALOG SOLUTION (Halcinonide Topical Solution, USP) 0.1% to the affected area two to three times daily. Occlusive Dressing Technique Occlusive dressings may be used for the management of psoriasis or other recalcitrant conditions. Apply the solution to the lesion, cover with a pliable nonporous film, and seal the edges. If needed, additional moisture may be provided by covering the lesion with a dampened clean cotton cloth before the nonporous film is applied or by briefly wetting the affected area with water immediately prior to applying the medication. The frequency of changing dressings is best determined on an individual basis. It may be convenient to apply Halcinonide Topical Solution, USP 0.1% under an occlusive dressing in the evening and to remove the dressing in the morning (i.e., 12-hour occlusion). When utilizing the 12-hour occlusion regimen, additional solution should be applied, without occlusion, during the day. Reapplication is essential at each dressing change. If an infection develops, the use of occlusive dressings should be discontinued and appropriate antimicrobial therapy instituted.
Contraindications
openFDA Drug LabelingCONTRAINDICATIONS Topical corticosteroids are contraindicated in those patients with a history of hypersensitivity to any of the components of the preparations.
Adverse Reactions
openFDA Drug LabelingADVERSE REACTIONS The following local adverse reactions are reported infrequently with topical corticosteroids, but may occur more frequently with the use of occlusive dressings (reactions are listed in an approximate decreasing order of occurrence): burning, itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration of the skin, secondary infection, skin atrophy, striae, and miliaria.
Description
openFDA Drug LabelingDESCRIPTION The topical corticosteroids constitute a class of primarily synthetic steroids used as anti-inflammatory and antipruritic agents. The steroids in this class include halcinonide. Halcinonide is designated chemically as 21-Chloro-9-fluoro-11β,16α, 17-trihydroxypregn-4-ene-3,20-dione cyclic 16,17-acetal with acetone. Graphic formula: C 24 H 32 ClFO 5 , MW 454.96, CAS-3093-35-4 Each mL of 0.1% HALOG SOLUTION (Halcinonide Topical Solution, USP) contains 1 mg halcinonide, edetate disodium, polyethylene glycol 300, and purified water with butylated hydroxytoluene as an antioxidant. halcinonide solution chemical structure
Overdosage
openFDA Drug LabelingOVERDOSAGE Topically applied corticosteroids can be absorbed in sufficient amounts to produce systemic effects (see PRECAUTIONS: General ).
How Supplied / Storage and Handling
openFDA Drug LabelingHOW SUPPLIED HALOG® SOLUTION (Halcinonide Topical Solution, USP) 0.1% is supplied in plastic squeeze bottles containing 120 mL (NDC 64950-127-12) of solution. Storage Store at room temperature; avoid freezing and temperatures above 104° F. To report SUSPECTED ADVERSE REACTIONS, contact Allucent at 1-866-511-6754 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. Distributed by: Genus Lifesciences Inc. Allentown, PA 18102 Revised: May 2025 5261181 50
Adverse event reports
Source: openFDA FAERSAttributed to this product's most-reported active ingredient: HALCINONIDE. Combination products with more than six active ingredients are not attributed, because a report count summed across a long ingredient list measures the list, not the medicine.
Packaging and NDCs
Source: NDC Directory| Package NDC | Product NDC | Labeler | Description | Marketing start |
|---|---|---|---|---|
| 0003-0249-15 | 0003-0249 | E.R. Squibb & Sons, L.L.C. | 20 mL in 1 BOTTLE, PLASTIC (0003-0249-15) | January 1, 2009 |
| 0003-0249-20 | 0003-0249 | E.R. Squibb & Sons, L.L.C. | 60 mL in 1 BOTTLE, PLASTIC (0003-0249-20) | January 1, 2009 |
| 64950-127-12 | 64950-127 | Genus Lifesciences Inc. | 1 BOTTLE, PLASTIC in 1 CARTON (64950-127-12) / 120 mL in 1 BOTTLE, PLASTIC | November 17, 2025 |
| 0003-0249 | 0003-0249 | E.R. Squibb & Sons, L.L.C. | — | January 1, 2009 |
| 64950-127 | 64950-127 | Genus Lifesciences Inc. | — | November 17, 2025 |
Sources for this page
| Dataset | Agency | Used for |
|---|---|---|
| NDC Directory | FDA | Identity, ingredients, strengths, forms, routes, labelers, packages |
| Drugs@FDA | FDA | Application, sponsor, submissions, review documents, marketing status |
| Orange Book | FDA | Therapeutic equivalence codes, reference drug flags, patents, exclusivity |
| Drug Labeling | FDA / NLM | Prescribing information reproduced above |
| FAERS | FDA | Adverse event report counts |
Generated September 25, 2026 · 12 sections on this page.